Share

June 2013; 3 (3) Drugs and Devices

Dimethyl fumarate for relapsing MS

Alessandro Serra, Robert J. Fox
First published June 10, 2013, DOI: https://doi.org/10.1212/CPJ.0b013e318296f10f
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
290

Share

Article Information

vol. 3 no. 3 249-253
DOI: 
https://doi.org/10.1212/CPJ.0b013e318296f10f
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published June 10, 2013.
Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Alessandro Serra, MD, PhD and
    2. Robert J. Fox, MD
  1. Alessandro Serra, MD, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Robert J. Fox, MD
    3. Scientific Advisory Boards:

    1. Biogen Idec, Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board, Neurology Editorial Board, Multiple Sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Allozyne, Avanir, Biogen Idec, Novartis, Questcor, and Teva Neurosciences.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research grant from Novartis.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society, RG 3548A2, 2004-2009; RG 4091A3/1 2009-2012; RG 4103A4/2, 2009-2011; RC 1004-A-5, 2010- 2012.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH.
  1. Correspondence to:
    foxr{at}ccf.org
View Full Text

Article usage

Article usage: May 2013 to December 2021

AbstractFullPdfSource
May 2013021Highwire
Jun 201361169120Highwire
Jul 20134451651Highwire
Aug 2013359724Highwire
Sep 201314137Highwire
Oct 2013185412Highwire
Nov 201323867Highwire
Dec 201318147Highwire
Jan 201412025Highwire
Feb 201411503Highwire
Mar 201411023Highwire
Apr 201410401Highwire
May 201410322Highwire
Jun 20149601Highwire
Jul 20147922Highwire
Aug 20148803Highwire
Sep 20149122Highwire
Oct 20148202Highwire
Nov 20148302Highwire
Dec 20144700Highwire
Jan 20155701Highwire
Feb 20156001Highwire
Mar 20153502Highwire
Apr 20153503Highwire
May 20151402Highwire
Jun 20152101Highwire
Jul 20151200Highwire
Aug 2015622Highwire
Sep 20151701Highwire
Oct 20151201Highwire
Nov 20151201Highwire
Dec 2015700Highwire
Jan 2016900Highwire
Feb 20162600Highwire
Mar 20161400Highwire
Apr 20161800Highwire
May 20164602Highwire
Jun 20161411Highwire
Jul 20161600Highwire
Aug 20161000Highwire
Sep 20161500Highwire
Oct 20161410Highwire
Nov 20161600Highwire
Dec 20161400Highwire
Jan 20171902Highwire
Feb 20171000Highwire
Mar 20171100Highwire
Apr 20171400Highwire
May 20171300Highwire
Jun 2017801Highwire
Jul 2017500Highwire
Aug 20171600Highwire
Sep 2017900Highwire
Oct 2017700Highwire
Nov 2017800Highwire
Dec 20171100Highwire
Jan 20181100Highwire
Feb 20182100Highwire
Mar 20182000Highwire
Apr 20181821Highwire
Apr 2018022pmc
May 20181801Highwire
Jun 20182400Highwire
Jun 2018344pmc
Jul 20182200Highwire
Aug 20181500Highwire
Aug 2018243pmc
Sep 20181101Highwire
Oct 2018900Highwire
Nov 20181100Highwire
Dec 2018800Highwire
Jan 20191100Highwire
Feb 20191000Highwire
Mar 20191800Highwire
Apr 20192400Highwire
May 20192400Highwire
Jun 20191200Highwire
Jul 20192100Highwire
Aug 20191000Highwire
Sep 2019700Highwire
Oct 2019500Highwire
Nov 2019801Highwire
Dec 2019700Highwire
Jan 2020700Highwire
Feb 2020700Highwire
Mar 2020500Highwire
Apr 2020500Highwire
May 2020700Highwire
Jun 2020400Highwire
Jul 2020600Highwire
Aug 20203200Highwire
Sep 2020800Highwire
Oct 2020700Highwire
Nov 20201100Highwire
Dec 2020600Highwire
Jan 2021900Highwire
Feb 2021700Highwire
Mar 20211400Highwire
Apr 20211000Highwire
May 2021500Highwire
Jun 20211810Highwire
Jul 20211911Highwire
Aug 20211600Highwire
Sep 2021900Highwire
Oct 20211500Highwire
Nov 20212100Highwire
Dec 20211300Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me